The importance of measuring anticardiolipin antibodies

Journal of Thrombosis and Haemostasis

Volumn 4, Issue 1, 2006, Pages 41-43

  De Groot, P G ^a   Derksen, R H W M ^b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b Department of Rheumatology and Clinical Immunology ^*  (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BETA2 GLYCOPROTEIN 1; BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; IMMUNOGLOBULIN A; GLYCOPROTEIN;

ANTIBODY DETECTION; ANTIPHOSPHOLIPID SYNDROME; DISEASE CLASSIFICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MEDICAL LITERATURE; NOTE; PREDICTION; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PUBLICATION; RISK FACTOR; STANDARDIZATION; THROMBOEMBOLISM; VEIN THROMBOSIS; BLOOD; PREDICTION AND FORECASTING;

ANTIBODIES, ANTICARDIOLIPIN; ANTIPHOSPHOLIPID SYNDROME; BETA 2-GLYCOPROTEIN I; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLYCOPROTEINS; HUMANS; PREDICTIVE VALUE OF TESTS; RISK FACTORS; VENOUS THROMBOSIS;

EID: 33644855163     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2005.01689.x     Document Type: Note

References (12)

1. Arnout J, Vermylen J. Current status and implications of autoimmune antiphospholipid antibodies in relation to thrombotic disease. J Thromb Haemost 2003; 1: 931-42.
2. Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, Brey R, Derksen R, Harris EN, Hughes GR, Triplett DA, Khamashta MA. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: Report of an international workshop. Arthritis Rheum 1999; 42: 1309-11.
3. 2-glycoprotein I dependent lupus anticoagulant highly correlates with thrombosis in the Antiphospholipid Syndrome. Blood 2004; 104: 3598 -3602.
4. Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: A systematic review of the literature. Blood 2003; 101: 1827-32.
5. Ginsburg KS, Liang MH, Newcomer L, Goldhaber SZ, Schur PH, Hennekens CH, Stampfer MJ. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med 1992; 117: 997-1002.
6. Runchey SS, Folsom AR, Tsai MY, Cushman M, McGovern PD. Anticardiolipin antibodies as a risk factor for venous thromboembolism in a population-based prospective study. Br J Haematol 2002; 119: 1005-10.
7. Naess IA, Christiansen SC, Cannegieter SC, Rosendaal FR, Hammerstroem J. A prospective study of anticardiolipin antibodies as a risk factor for venous thrombosis in a general population (the HUNT study). J Thromb Haemost 2006; 4: 44-9.
8. Reber G, Schousboe I, Tincani A, Sanmarco M, Kveder T, De Moerloose P, Boffa MC, Arvieux J. Inter-laboratory variability of anti-beta2-glycoprotein I measurement. A collaborative study in the frame of the European Forum on Antiphospholipid Antibodies Standardization Group. Thromb Haemost 2002; 88: 66-73.
9. Arvieux J, Darnige L, Hachulla E, Roussel B, Bensa JC, Colomb MG. Species specificity of anti-beta 2 glycoprotein I autoantibodies and its relevance to anticardiolipin antibody quantitation. Thromb Haemost 1999; 75: 725-30.
10. Sletnes KE, Wisloff F, Smith P, Arnesen H, Abdelnoor M. Antiphospholipid antibodies after myocardial infarction and their relationship to mortality, reinfarction and non-haemmorrhagic stroke. Lancet 1992; 339: 451-3.
11. de Groot PG, Lutters B, Derksen RHWM, Lisman T, Meijers JCM, Rosendaal FR. Lupus anticoagulants and the risk of a first episode of deep venous thrombosis. J Thromb Haemostas 2005; 3: 1993-7.
12. Galli M, Luciani D, Bertolini G, Barbui T. Anti-beta2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome. Blood 2003; 102: 2717-23.